Pharmaceuticals, Biotechnology and Life Sciences
UGN-101: Consistent Complete Response (CR) Rate of 59 Percent in Patients with Low-Grade Upper Tract Urothelial Cancer (LG UTUC) Durability…
TARIS Bio posted on Wednesday positive data from its Phase 1b study of TAR-200 for the treatment of patients with muscle invasive bladder cancer (MIBC), neoadjuvant to radical cystectomy (RC).
Merck’s anti PD-1 therapy Keytruda has been approved by the Japanese Ministry of Health, Labor and Welfare (MHLW) to treat…
AstraZeneca’s application (BLA) for durvalumab for BLA in bladder cancer was accepted by the FDA. The PD-L1 human monoclonal antibody…
Merck announced that the phase 3 keynote-045 trial investigating the use of Keytruda (pembrolizumab), the company’s anti-PD-1 therapy, in patients with previously treated advanced urothelial cancer, met the primary endpoint of overall survival (OS).